Martine A. Rothblatt, who serves as Chairperson and Chief Executive Officer of United Therapeutics Corporation (NASDAQ: UTHR), executed a sale of 9,500 common shares on April 17, 2026, resulting in proceeds of approximately $5.57 million. The disposition was carried out under a pre-established 10b5-1 trading arrangement.
On the same date, Rothblatt exercised stock options to acquire 9,500 shares at an exercise price of $146.03 per share, representing an aggregate outlay of about $1.39 million. The shares sold that day were the same shares obtained through that option exercise.
The reported sale prices for the common stock ranged between $575.38 and $592.30 per share. Those transactions came as United Therapeutics' shares were trading near a 52-week high of $607.89, after the stock returned roughly 107% over the prior 12 months.
10b5-1 plan details and holdings
The trading plan referenced was adopted on November 7, 2025, and is structured to remain in effect until the earlier of the exercise of 1,734,410 stock options or December 31, 2026. Following the April 17 transactions, Rothblatt's direct ownership of United Therapeutics common stock stands at 40,513 shares. She also has indirect holdings that include 166 shares held by her spouse and 639,118 shares held in various family trusts. In addition to those equity positions, Rothblatt holds 17,000 derivative shares represented by stock options.
Company developments and clinical progress
United Therapeutics has reported a series of operational updates in recent weeks. The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to the company's investigational liver device, miroliverELAP, which is intended to provide temporary support for patients with acute liver failure.
The company is also scheduled to present 11 data presentations at the upcoming International Society for Heart and Lung Transplantation Annual Meeting. Those presentations will include interim analyses from the PHINDER and ARTISAN studies, which focus on therapies related to pulmonary hypertension and arterial hypertension.
Analyst coverage and price targets
Recent analyst activity has accompanied the clinical and regulatory news. Raymond James initiated coverage of United Therapeutics with an Outperform rating and a $700 price target, citing potential peak sales of more than $5 billion for Tyvaso in idiopathic pulmonary fibrosis. H.C. Wainwright raised its price target to $660 and kept a Buy rating, referencing promising TETON-1 trial data for Tyvaso. BofA Securities increased its target to $626 while maintaining a Neutral rating, following positive Phase 3 TETON-1 results.
Separately, InvestingPro analysis cited in public reporting indicates that, based on its Fair Value methodology, United Therapeutics' shares currently appear overvalued relative to that Fair Value assessment. A Pro Research Report on UTHR is available through that research platform.
Context for investors
The confluence of insider activity, regulatory designations, clinical data disclosures and analyst target revisions provides multiple data points market participants can consider. The CEO's exercise and immediate sale under a 10b5-1 plan is consistent with a prearranged approach to liquidity from vested options, while the company's clinical milestones and analyst updates speak to ongoing efforts to expand therapeutic applications and commercial potential.
Where available information is limited, readers should note that the trading plan specifies the maximum option exercise count and end date but does not elaborate on additional potential future dispositions or the timing of remaining option exercises beyond those terms.